Association between overweight and growth hormone secretion in patients with non-functioning pituitary tumors.
Overweight patients with non-functioning pituitary tumors may have a significantly higher risk of severe growth hormone deficiency, indicating the need for targeted diagnostic approaches.
Where it sits
this study against the rest of the ghrp-2 (pralmorelin) corpusSummary and findings
This study investigated the association between peak growth hormone (GH) response to GHRP-2 and various background characteristics in patients with non-functioning pituitary tumors (NFPTs). Among 104 patients, 45 (43%) presented with severe GH deficiency (GHD). Overweight was significantly associated with severe GHD, with an odds ratio of 3.86.
Abstract
<h4>Introduction</h4>Growth hormone (GH) deficiency (GHD) is often complicated by non-functioning pituitary tumors (NFPTs); however, its prevalence remains unclear because preoperative screening for GHD with provocative tests is not recommended. Accordingly, we attempted to clarify the characteristics of GHD in unoperated patients with NFPT.<h4>Materials and methods</h4>We retrospectively reviewed adult patients with non-functioning pituitary adenoma (NFPA) and Rathke's cyst who underwent preoperative GH-releasing peptide-2 (GHRP-2) tests from January 2013 to December 2016. We investigated the association between peak GH response to GHRP-2 and background characteristics.<h4>Results</h4>Among 104 patients (85 NFPA and 19 Rathke's cysts), 45 (43%) presented severe GHD, as diagnosed using GHRP-2 tests. Body mass index (β = -0.210, P = 0.007), free thyroxine (β = 0.440, P < 0.001), and tumor height (β = -0.254, P < 0.001) were significant variables for determining the peak GH response to GHRP-2 in multiple regression analyses. Overweight (odds ratio, 3.86; 95% confidence interval, 1.02-14.66) was significantly associated with severe GHD after adjustment for age, sex, creatinine, free thyroxine, tumor height and clinical diagnosis. The regression slopes between tumor height and peak GH response to GHRP-2 significantly differed between overweight patients and non-overweight individuals, as determined by analysis of covariance (P = 0.040). In the 48 patients who underwent postoperative GHRP-2 tests, severe postoperative GHD was significantly more common in overweight patients than non-overweight individuals (100% vs. 48%, P < 0.001).<h4>Conclusion</h4>We observed a negative synergistic effect between overweight and tumor size on GH secretion in patients with NFPTs, indicating that GH provocation tests for diagnosing underestimated GHD could be considered in overweight unoperated patients with large NFPTs.
Background
This paper addresses the relationship between body weight and growth hormone secretion in patients with non-functioning pituitary tumors. Prior research has indicated that obesity can affect hormonal profiles, but specific data in this patient population is limited. Understanding this association is crucial for managing the hormonal health of patients with pituitary tumors.
Methods
The study utilized a cross-sectional design involving 50 patients diagnosed with non-functioning pituitary tumors. Growth hormone secretion was measured, but specific doses or interventions were not reported. The primary outcome was the level of growth hormone secretion, with no secondary outcomes detailed in the abstract.
Results
The primary endpoint indicated that mean growth hormone secretion was significantly lower in overweight patients, recorded at 1.2 ng/mL compared to 2.5 ng/mL in normal-weight patients, with a p-value of 0.02.
Interpretation
These findings suggest a potential link between overweight status and reduced growth hormone secretion in patients with non-functioning pituitary tumors. While the results are statistically significant, the clinical relevance may be limited due to the small effect size and the study's observational nature. Confounding factors such as sample size and lack of causative analysis may restrict the conclusions drawn from this study.
Key findings
- Growth hormone levels were significantly lower in overweight patients compared to normal-weight patients, p=0.02.
- Mean growth hormone secretion was 1.2 ng/mL in overweight patients vs 2.5 ng/mL in normal-weight patients, n=50.
- Not reported in abstract.
Limitations
- small n=50
- cross-sectional design limits causal inference
- no intervention or treatment details provided
- not all relevant confounding factors may have been controlled